阳离子药物与 COVID-19。
Cationic drugs and COVID-19.
机构信息
Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, Milan, Italy.
Retired Professor.
出版信息
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966078. doi: 10.1177/2058738420966078.
Abstract
Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.
摘要
鉴于 COVID-19 疫情在全球范围内迅速蔓延，我们开始考虑许多阳离子药物（即在生理 pH 值下存在一个或多个阳离子基团的药物，包括伯、仲、叔和胍基氨基基团）可能会对 SARS-CoV2 进入宿主细胞产生影响。这可能为对抗 COVID-19 开辟新的治疗机会。
相似文献
1
Cationic drugs and COVID-19.阳离子药物与 COVID-19。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966078. doi: 10.1177/2058738420966078.
2
Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?目前针对新型冠状病毒肺炎有哪些可用的治疗选择？
Antiinflamm Antiallergy Agents Med Chem. 2020;19(2):85-87. doi: 10.2174/1871523019999200228100917.
3
COVID-19: A Defining Moment for Clinical Pharmacology?新型冠状病毒肺炎：临床药理学的决定性时刻？
Clin Pharmacol Ther. 2020 Jul;108(1):11-15. doi: 10.1002/cpt.1876.
4
Drug Discovery Strategies for SARS-CoV-2.针对 SARS-CoV-2 的药物研发策略。
J Pharmacol Exp Ther. 2020 Oct;375(1):127-138. doi: 10.1124/jpet.120.000123. Epub 2020 Jul 28.
5
Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.药物重新利用研究确定了潜在的新冠病毒抗病毒药物。
JAMA. 2020 Sep 8;324(10):928. doi: 10.1001/jama.2020.15948.
6
Imatinib is not a potent anti-SARS-CoV-2 drug.伊马替尼不是一种有效的抗SARS-CoV-2药物。
Leukemia. 2020 Nov;34(11):3085-3087. doi: 10.1038/s41375-020-01045-9. Epub 2020 Sep 30.
7
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
8
Repurposing old drugs as antiviral agents for coronaviruses.将老药重新用作冠状病毒的抗病毒药物。
Biomed J. 2020 Aug;43(4):368-374. doi: 10.1016/j.bj.2020.05.003. Epub 2020 May 23.
9
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.SARS-CoV-2 刺突蛋白的结构和功能特性：COVID-19 的潜在抗病毒药物研发。
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. doi: 10.1038/s41401-020-0485-4. Epub 2020 Aug 3.
10
Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）直接感染心脏会加重新型冠状病毒肺炎（COVID-19）的心血管后遗症。
Drug Discov Today. 2020 Sep;25(9):1559-1560. doi: 10.1016/j.drudis.2020.06.021. Epub 2020 Jun 24.
引用本文的文献
1
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.二甲双胍对严重 COVID-19 的保护作用：深入的机制分析。
Diabetes Metab. 2022 Jul;48(4):101359. doi: 10.1016/j.diabet.2022.101359. Epub 2022 May 31.
2
Development of a Promising Method for Producing Oligomeric Mixture of Branched Alkylene Guanidines to Improve Substance Quality and Evaluate Their Antiviral Activity against SARS-CoV-2.开发一种有前途的方法来生产支化亚烷基胍的低聚混合物，以提高物质质量，并评估其对 SARS-CoV-2 的抗病毒活性。
Molecules. 2021 Jun 7;26(11):3472. doi: 10.3390/molecules26113472.
本文引用的文献
1
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.追踪 SARS-CoV-2 刺突蛋白的变化：D614G 增加 COVID-19 病毒感染力的证据。
Cell. 2020 Aug 20;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043. Epub 2020 Jul 3.
2
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system.社论：尼古丁与严重急性呼吸综合征冠状病毒2：2019冠状病毒病可能是一种烟碱能胆碱能系统疾病。
Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. eCollection 2020.
3
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
4
COVID-19 and diabetes: Can DPP4 inhibition play a role?2019冠状病毒病与糖尿病：二肽基肽酶4抑制作用能否发挥作用？
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
5
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.TMPRSS2：抗流感病毒和冠状病毒感染治疗的潜在靶标。
Biochimie. 2017 Nov;142:1-10. doi: 10.1016/j.biochi.2017.07.016. Epub 2017 Aug 1.
8
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.二肽基肽酶 4 是新兴的人类冠状病毒-EMC 的功能性受体。
Nature. 2013 Mar 14;495(7440):251-4. doi: 10.1038/nature12005.
9
Multifarious roles of sialic acids in immunity.唾液酸在免疫中的多样作用。
Ann N Y Acad Sci. 2012 Apr;1253(1):16-36. doi: 10.1111/j.1749-6632.2012.06517.x.
10
The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages.碱性物质和酸性离子载体对小鼠腹腔巨噬细胞中外源和内源性蛋白质消化的影响。
J Cell Biol. 1986 Mar;102(3):959-66. doi: 10.1083/jcb.102.3.959.
Zotero 插件